Investor Presentation Q1 2018

Investor Presentation First three months of 2018 Slide 91 Strong growth among long-acting haemophilia B products as Refixia®/RebinynⓇ is set for launch in the EU and the USA Reported recombinant FIX sales RefixiaⓇ/RebinynⓇ launched in first countries Sales (USD million) 1,400 1,200 1,000 800 600 400 200 0 2011 Benefix® AlprolixⓇ CAGR: 10.1%¹ IdelvionⓇ • Launched in the first EU countries in 2017 • Launched in the USA in February 2018 2017 • RefixiaⓇ/RebinynⓇ offers a unique clinical profile that brings factor levels into the non-haemophilia range for adults and adolescents • Dialogue ongoing with the FDA and EMA to establish path forward to obtain routine prophylaxis indication in the USA and complete paediatric indication in Europe to include children younger than 12 years old 1 CAGR for 6-year period FIX: Coagulation factor IX Source: Company reports (Does not include RixubisⓇ as sales are not reported separately). changing FDA: US Food and Drug Administration; EMA: European Medicines Agency rFIX: Recombinant coagulation factor IX diabetes® novo nordisk

View entire presentation